Komori
Share Issuance and Disposal4586Medrx Co.,Ltd.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 35th Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Clause)

In July 2026, 59,365 of the 35th Stock Acquisition Rights were exercised, and 5,936,500 new shares were delivered. As of the end of the month, 79,395 Stock Acquisition Rights remained unexercised (representing 7,939,500 shares).

Worth reading
80Important
Scored from 2 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
5936500
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise status report for the 35th Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)

発行・処分する株式数5,936,500Shares

Number of shares delivered during the month: 5,936,500 new shares (no treasury shares transferred)

Intended allottee
Growth Capital Co., Ltd. (allottee of the previously issued rights)
Existing Shares and Increase
+10.00%Rate of increase
60,271,100 shares66,207,600Shares

The number of shares delivered during the month represented 10.00% of the 59,365,100 listed shares outstanding as of the payment date for the issuance (exercise ratio subject to exercise restrictions).

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The Exercise Prices during the reporting month were ¥46, ¥49, ¥50, ¥57 and ¥59. Details of the adjustment clause and the floor price: not disclosed
Number of Stock Acquisition Rights
Total issued: 147,820; exercised during the reporting month: 59,365; unexercised at the end of the preceding month: 138,760; unexercised at the end of the month: 79,395
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
5 June 2026: Issuance of the 35th Stock Acquisition Rights (with Exercise Price Adjustment Clause), with Growth Capital Co., Ltd. as the allottee (total issued: 147,820)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise status report for the 35th Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Number of shares to be issued or disposed ofNumber of shares delivered during the month: 5,936,500 new shares (no treasury shares transferred)
Intended allotteeGrowth Capital Co., Ltd. (allottee of the previously issued rights)
Dilution RateThe number of shares delivered during the month represented 10.00% of the 59,365,100 listed shares outstanding as of the payment date for the issuance (exercise ratio subject to exercise restrictions).
Total number of issued shares60,271,100 shares (as of the end of the month preceding the reporting month, including 2 treasury shares) → 66,207,600 shares (assuming the number of shares delivered during the reporting month is added to the number of shares outstanding as of the end of the preceding month)
Exercise priceThe Exercise Prices during the reporting month were ¥46, ¥49, ¥50, ¥57 and ¥59. Details of the adjustment clause and the floor price: not disclosed
Number of Stock Acquisition RightsTotal issued: 147,820; exercised during the reporting month: 59,365; unexercised at the end of the preceding month: 138,760; unexercised at the end of the month: 79,395
Procedures under the Corporate Code of ConductThe disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing5 June 2026: Issuance of the 35th Stock Acquisition Rights (with Exercise Price Adjustment Clause), with Growth Capital Co., Ltd. as the allottee (total issued: 147,820)
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status of these Stock Acquisition Rights in July 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 35th Stock Acquisition Rights Issued through a Third-Party Allotment (with Exercise Price Adjustment Clause) | Medrx Co.,Ltd. (4586) timely disclosure | Komori